Description

Premium CJC-1295 with DAC – 5mg Research Grade

Product Overview

If you are looking for CJC-1295 with DAC for laboratory research in the UK, Cocer Peptides supplies a high-purity, research-grade version of this long-acting growth hormone-releasing hormone (GHRH) analogue. It is a synthetic 30-amino acid peptide incorporating a Drug Affinity Complex (DAC) that enables in-vivo bioconjugation with endogenous serum albumin, significantly extending its half-life compared with unmodified GHRH .

The defining feature of this compound is its extended activity profile. According to research published in the Journal of Clinical Endocrinology & Metabolism, the estimated half-life of CJC-1295 with DAC was 5.8–8.1 days in healthy adults following subcutaneous administration. After multiple doses, mean IGF-I levels remained above baseline for up to 28 days . This prolonged pharmacokinetic profile distinguishes it from short-acting GHRH analogues and makes it a unique tool for studying sustained growth hormone axis stimulation.

Researchers seeking this peptide typically need material with complete analytical documentation. Every batch from Cocer Peptides includes a Certificate of Analysis (COA) showing HPLC purity and mass spectrometry confirmation.

Important Notice: This product is supplied for laboratory research use only and is not intended for human or veterinary use. It is not authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) as a medicine. Under World Anti-Doping Agency (WADA) rules, CJC-1295 is classified as a prohibited substance under Section S2 .

Product Specifications

Mechanism of Action

Albumin Binding and Extended Half-Life

CJC-1295 with DAC incorporates a maleimidopropionyl moiety attached to a lysine residue, which enables covalent binding to cysteine residues on serum albumin following administration . This albumin conjugation is the primary mechanism responsible for the peptide’s extended circulation time. According to the FDA’s evaluation of CJC-1295-related substances, the DAC modification “contributes to the greater stability and longer half-life of CJC-1295 DAC compared to GHRH1-29” .

Research published in the American Journal of Physiology demonstrated that once-daily administration was sufficient to maintain normal growth parameters and body composition in GHRH knockout mouse models . The study also noted that the compound has important trophic effects on GH-secreting cells of the pituitary .

Growth Hormone and IGF-1 Stimulation

This peptide acts as a growth hormone secretagogue, stimulating the pituitary gland to release endogenous growth hormone. In the Teichman et al. study published in the NIH PubMed database, a single injection produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 days .

Unlike exogenous growth hormone administration, CJC-1295 with DAC preserves the body’s natural feedback mechanisms. Research indexed through the NIH PubMed database indicates that pulsatile GH secretion persists during continuous stimulation .

Research Applications

Growth Hormone Axis Studies

This compound is a foundational tool for investigating the GHRH receptor and its role in pulsatile GH secretion. The peptide’s extended half-life enables researchers to study sustained versus pulsatile growth hormone release patterns within a single experimental system . According to a review published in Frontiers in Endocrinology, CJC-1295 with DAC produces “sustained ↑ endogenous GH secretion → consequent ↑ IGF-1” .

Body Composition and Metabolic Research

Research has explored CJC-1295 with DAC for its effects on body composition and metabolic parameters. The Frontiers review notes “potential metabolic/anabolic benefits through sustained GH/IGF-1 elevation, including favourable shifts in body composition (e.g., increased lean mass, reduced adiposity) and enhanced metabolic signaling” . These findings support the compound’s use in metabolic research models.

Combination Studies with Ipamorelin

CJC-1295 with DAC is frequently studied alongside Ipamorelin, a selective ghrelin receptor agonist. This combination is investigated because the two compounds act through complementary pathways: CJC-1295 activates the GHRH receptor, while Ipamorelin activates the ghrelin receptor (GHSR-1a) . Research models indicate this dual-pathway approach produces amplified GH release compared with either mechanism alone.

Quality and Purity

Every batch of CJC-1295 with DAC from Cocer Peptides undergoes rigorous quality control:

• ≥98% purity verified by HPLC

• Molecular weight confirmed by mass spectrometry

• Batch number matching the vial label

• Certificate of Analysis (COA) available on request

The FDA’s evaluation of CJC-1295-related substances noted that critical characterization data, including impurities, aggregates, and endotoxin levels, were lacking in publicly available literature . For researchers sourcing this peptide, batch-level analytical documentation is therefore essential for ensuring experimental reproducibility.

According to MHRA guidance, selling or supplying unlicensed medicinal products in the UK is unlawful, and consumers should verify the legality of their purchase sources.

Frequently Asked Questions

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic GHRH analogue incorporating a Drug Affinity Complex that binds to serum albumin, extending its half-life to approximately 5.8–8.1 days . It is studied for its effects on growth hormone and IGF-1 secretion.

What does DAC stand for?

DAC stands for Drug Affinity Complex. It enables the peptide to bind covalently to serum albumin, significantly extending its circulation time compared with unmodified GHRH .

Is CJC-1295 with DAC approved for human use?

No. It has not been approved by the MHRA or FDA for any indication. The FDA’s evaluation raised concerns regarding nonclinical toxicity signals and lack of clinical effectiveness data in relevant patient populations .

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC has an extended half-life (5.8–8.1 days) due to albumin binding, while the without-DAC form (Mod GRF 1-29) has a short half-life of approximately 30 minutes. The DAC version produces sustained GH elevation, while the without-DAC version produces brief GH pulses .

What purity level can I expect?

Our CJC-1295 with DAC is provided at ≥98% purity, verified by HPLC with third-party testing.

How should CJC-1295 with DAC be stored?

Store lyophilized powder at -20°C, protected from light and moisture. Reconstituted material should be stored at 2–8°C and used promptly following standard laboratory protocols .

Conclusion

CJC-1295 with DAC represents a valuable research tool for investigating sustained growth hormone axis stimulation, GHRH receptor pharmacology, and metabolic regulation. Its Drug Affinity Complex enables extended circulation time through albumin binding, making it distinct from short-acting GHRH analogues. For laboratories seeking this peptide in the UK, Cocer Peptides offers high-purity material with complete analytical documentation and batch-specific COA support. Researchers purchasing CJC-1295 with DAC should ensure the material is used solely for legitimate in-vitro research purposes.

Ready to Advance Your Research?

Order premium CJC-1295 with DAC (5mg) for your laboratory today.

Shop CJC-1295 with DAC Now | Contact Our Research Team